France Mouth Ulcer Therapeutics Market Analysis

France Mouth Ulcer Therapeutics Market Executive Summary

The France Mouth Ulcer Therapeutics Market was valued at $41.8 Mn in 2023 and is projected to grow at a CAGR of 2.9% from 2023 to 2023, to $51.1 Mn by 2030.

Mouth ulcers, also known as canker sores, are painful and uncomfortable lesions that can appear in various areas of the mouth and gums. Symptoms include one or more painful sores with red edges and a yellow, white, or gray centre, fever, sluggishness, and swollen glands during extreme outbreaks. Causes include stress, anxiety, or hormonal changes, minor mouth injuries, dental appliances or poorly fitting dentures, certain medications, genetic predisposition, nutritional deficiencies, specific medical conditions, allergic reactions to certain foods, toothpastes, or mouthwashes, and vitamin deficiencies. Treatment involves symptomatic relief with topical gels containing anaesthetics, antiseptics, and antibiotics, as well as supportive care with multivitamins or vitamin supplements, antipyretics, and antibiotics. Medications include antibiotics, oral painkillers, oral steroids, antiseptics, chlorhexidine gluconate mouthwash, and sucralfate. Home care includes good oral hygiene, avoiding trigger foods, warm saline gargles, ice packs, and a balanced diet. Medical attention is necessary if the ulcers fail to heal within a week or two, are unusual, spreading, or large, or if there is severe pain, fever, or difficulty while chewing, talking, or swallowing.

The prevalence rate of mouth ulcers in France is 14.8%. The market therefore is driven by significant factors like the increasing prevalence rate mouth ulcers, rising awareness about oral hygiene, and supportive government initiatives, however, factors such as limited accessibility, availability of substitute treatments and budgetary constraints limit market growth.

The industry is primarily dominated by players such as Servier, Teva, Mylan, Bayer, Pfizer, Takeda Pharmaceuticals, AstraZeneca, Sanofi and GSK among others.

Market Dynamics

Market Growth Drivers

Increasing Awareness: Growing awareness of the significance of proper oral hygiene and the range of treatment options for mouth ulcers is fuelling market expansion. Public health campaigns and educational efforts are raising knowledge about the causes, symptoms, and risks of mouth ulcers. As more individuals become educated, they are more inclined to pursue suitable treatments, resulting in increased demand for effective solutions.

Government Support: The French government has implemented initiatives and campaigns aimed at promoting oral health education and raising awareness about various oral health issues, including mouth ulcers. These efforts play a crucial role in educating the public, encouraging early diagnosis, and promoting the adoption of effective treatment options. Government support through policies, programs, and resource allocation contributes to market growth by increasing accessibility and affordability of treatments.

Rise in Prevalence: The rise in the prevalence of mouth ulcers due to various factors, such as tobacco consumption, unhealthy lifestyles, and stress, contributes to market growth. In 2021, 10.2% of youths in France smoke tobacco. As the number of individuals affected by mouth ulcers increases, the demand for effective treatment options also rises.

Market Restraints

Competition from Home Remedies: The availability of home remedies and over-the-counter medications provides more affordable alternatives to pharmaceutical treatments for mouth ulcers. These alternatives can be appealing to individuals with limited financial resources or those seeking more natural approaches. The competition from these alternatives constrains the growth of the pharmaceutical mouth ulcer treatment market.

Limited Accessibility to Pharmaceuticals: In some areas of France, access to pharmaceutical treatments for mouth ulcers may be limited due to cost or availability issues. Factors such as geographical location, healthcare infrastructure, and affordability can restrict access to these treatments. This limited accessibility can hinder market growth and limit the reach of effective pharmaceutical treatments.

Budget Constraints: Financial limitations can greatly affect a person's capacity to pay for medications for mouth ulcers. Patients might choose to spend their money on more urgent needs rather than on treatments for mouth ulcers, resulting in reduced demand for these drugs. Budgetary constraints can prevent people from accessing and using effective treatments, thereby hindering market expansion.

Regulatory Landscape and Reimbursement Scenario

In France, marketing authorization for drugs can be obtained at the national or European level. The French regulatory agency for drugs is the National Agency for the Safety of Medicine and Health Products (ANSM) previously known as the French Agency for the Medical Safety of Health Products. In Europe, the regulatory agency for drugs is the European Medicines Agency (EMA).

The National Agency for the Safety of Medicine and Health Products (ANSM) is the French regulatory agency for drug approval at the national level and at the European level, the European Medicines Agency (EMA) grants marketing authorization. The Transparency Committee (CT) of the French National Authority for Health (HAS) assesses a new drug's medical benefit (SMR) and improvement of medical benefit (ASMR). Based on the ASMR, the Economic Committee on Healthcare Products (CEPS) sets drug prices through negotiations with pharmaceutical companies. The National Healthcare Insurances (UNCAM) determines the reimbursement rate, ranging from 100% for major SMR to no reimbursement for insufficient SMR, based on the SMR level. The Health Ministry makes the final decision on including the drug in the reimbursable medicines list for 5 years, subject to reevaluation.

In France, the percentage of individuals covered by private health insurance is about 95%, and public health insurance expenses are shifting toward private health insurance, resulting in a continuous increase in copayments.

Competitive Landscape

Key Players

Here are some of the major key players in the France Mouth Ulcers Therapeutics Market:

• Servier
• Pfizer, Inc.
• GlaxoSmithKline plc.
• Reckitt Benckiser
• Teva
• Takeda Pharmaceuticals
• Bayer
• Mylan
• AstraZeneca
• Sanofi